Appeal No. 2001-1586 Page 2
Application No. 08/402,394
Claim 33 and 42 are representative of the subject matter on appeal and reads as
follows:1
33. A compound of the formula I
B(1-30)-Arg-A(1-21)
(I)
wherein A(1-21) and B(1-30) denote the A and B chains of human insulin.
42. A method for the preparation of a mono-Arg-insulin compound of the formula II
S – S
| |
A(1 – 21)
| |
S – S
| | (II)
S – S
| |
B(1 – 30)-Arg
in which A(1-21) and B(1-30) denote the A and B chains of human insulin and the –S-S-
bridges are positioned as in insulin, which comprises:
(a) expressing a DNA sequence encoding a mini-proinsulin compound of the
formula:
B(1-30)-Arg-A(1-31)
in a yeast; and
(b) cleaving said mini-proinsulin compound with trypsin.
The references relied upon by the examiner are:
Mai et al. (Mai) 5,087,564 Feb. 11, 1992
Markussen et al. (Markussen ‘212) 4,916,212 Apr. 10, 1990
Grau (Grau ‘684) 4,801,684 Jan. 31, 1989
Grau (Grau ‘332) 4,639,332 Jan 27, 1987
1 We note that claim 42(a) requires the use of the compound B(1-30)-Arg-A(1-31) instead of B(1-30)-Arg-
A(1-21). We view “A(1-31)” in the claim to be a typographical error as all references to this compound in
the original disclosure of this application state that the A chain is depicted as “A(1-21).” Claim 21 also
contains this apparent error. Our consideration of the issues raised in this appeal has been based upon
claim 42(a) requiring the use of the compound B(1-30)-Arg-A(1-21). Note counsel’s statement at page 8
of the Appeal Brief “the common subject matter to every pending claim is the compound of formula
B(1-30)-Arg-A(1-21).”
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007